Trial Outcomes & Findings for A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures (NCT NCT01618695)

Last Updated: 2021-07-29

Results Overview

Seizure frequency was based on number of seizures per 28 days, calculated as the number of seizures over the entire time interval divided by the number of days in the interval and multiplied by 28. All partial seizure included simple partial seizures without motor signs, simple partial with motor signs, complex partial, and complex partial with secondary generalized seizures. A simple partial seizure takes place on one side of the brain. Usually, people experiencing a simple partial seizure do not lose consciousness or awareness. A complex partial seizure is a type of seizure that arises in one lobe of the brain, rather than the whole brain. The seizure affects people's awareness and may cause them to lose consciousness.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

940 participants

Primary outcome timeframe

Baseline, Week 19

Results posted on

2021-07-29

Participant Flow

Participants took part in the study at 119 investigative sites in Australia, China, Korea, Japan, Malaysia, Taiwan, and Thailand from 15th May 2012 to 28th May 2020. A total of 940 participants were enrolled and screened, of which 230 participants were screen failures, 710 participants were randomized and 707 participants were treated in this study.

This study included Core and Extension Phase. Core Phase consisted of 2 phases: Prerandomization (Baseline) and Randomization (Titration, Maintenance Period). Extension Phase consisted of 3 periods: Preconversion, Conversion, Maintenance Period. Participants received varying doses depending on which dose level they were assigned to in Core Phase and their individual tolerance but in Extension Phase, all participants were up-titrated to single target dose level of 12 milligram (mg) per day.

Participant milestones

Participant milestones
Measure	Core Phase: Placebo; Extension Phase: up to 12 mg Perampanel Participants received perampanel-matched placebo tablets (6 tablets), orally, once daily before bedtime from Week 0 up to Week 18 (up to 19 weeks) in the Core Phase. Participants received placebo in Extension Phase as they received in Core Phase, orally, once daily before bedtime from Week 19 to Week 22 (preconversion period). Participants started receiving perampanel 2 mg tablet, orally, once daily which was then titrated as 2 mg weekly increments up to a maximum dose of 12 mg, orally, once daily up to Week 28 (conversion period). All participants could have their dose down or up titrated until an optimal dose was reached. After the conversion period, participants entered a maintenance period in which they received the perampanel dose orally, once daily, that provided the optimal combination of efficacy and tolerability before bedtime up to Week 75 or longer depending on the requirements of each country in the Extension Phase.	Core Phase: Perampanel 4 mg; Extension Phase: up to 12 mg Perampanel Participants received perampanel 2 mg tablet, orally, once daily before bedtime in Week 0 and then titrated up to maximum dose of 4 mg orally, once daily from Week 1 up to Week 5 (titration period), followed by perampanel 4 mg, orally, once daily from Week 6 up to Week 18 (maintenance period) in the Core Phase. Total duration of titration and maintenance period in Core Phase was 19 weeks. Participants received the same dose of perampanel 4 mg in Extension Phase as they received in Core Phase, orally, once daily before bedtime from Week 19 to Week 22 (preconversion period). Participants started receiving perampanel 4 mg tablet, orally, once daily which was then titrated as 2 mg weekly increments up to a maximum dose of 12 mg, orally, once daily up to Week 28 (conversion period). All participants could have their dose down or up titrated until an optimal dose was reached. After the conversion period, participants entered a maintenance period in which they received the perampanel dose orally, once daily, that provided the optimal combination of efficacy and tolerability before bedtime up to Week 75 or longer depending on the requirements of each country in the Extension Phase.	Core Phase: Perampanel 8 mg; Extension Phase: up to 12 mg Perampanel Participants received perampanel 2 mg tablet, orally, once daily before bedtime in Week 0 and then titrated up to maximum dose of 8 mg (weekly increment of 2 mg from Week 1 up to Week 3) orally, once daily for up to Week 5 (titration period), followed by perampanel 8 mg, orally, once daily from Week 6 up to Week 18 (maintenance period) in the Core Phase. Total duration of titration and maintenance period was 19 weeks in the Core Phase. Participants received the same dose of perampanel 8 mg in the Extension Phase as they received in Core Phase, orally, once daily before bedtime from Week 19 to Week 22 (preconversion period). Participants started receiving perampanel 8 mg tablet, orally, once daily which was then titrated as 2 mg weekly increments up to a maximum dose of 12 mg, orally, once daily up to Week 28 (conversion period). All participants could have their dose down or up titrated until an optimal dose was reached. After the conversion period, participants entered a maintenance period in which they received the perampanel dose orally, once daily, that provided the optimal combination of efficacy and tolerability before bedtime up to Week 75 or longer depending on the requirements of each country in the Extension Phase.	Core Phase/Extension Phase: up to 12 mg Perampanel Participants received perampanel 2 mg tablet, orally, once daily before bedtime in Week 0 and then titrated up to maximum dose of 12 mg (weekly increment of 2 mg from Week 1 up to Week 5) orally, once daily for up to Week 5 (titration period), followed by perampanel 12 mg, orally, once daily from Week 6 up to Week 18 (maintenance period) in the Core Phase. Total duration of titration and maintenance period was 19 weeks in the Core Phase. Participants received the same dose of perampanel 12 mg in the Extension Phase as they received in Core Phase, orally, once daily before bedtime from Week 19 to Week 22 (preconversion period) and continued receiving perampanel 12 mg, orally, once daily up to Week 28 (conversion period). All participants could have their dose down or up titrated until an optimal dose was reached. After the conversion period, participants entered a maintenance period in which they received the perampanel dose orally, once daily, that provided the optimal combination of efficacy and tolerability before bedtime up to Week 75 or longer depending on the requirements of each country in the Extension Phase.
Core Phase STARTED	177	176	177	180
Core Phase Treated (Safety Analysis Set)	176	176	175	180
Core Phase COMPLETED	152	156	147	144
Core Phase NOT COMPLETED	25	20	30	36
Extension Phase STARTED	151	156	146	143
Extension Phase COMPLETED	56	40	54	46
Extension Phase NOT COMPLETED	95	116	92	97

Reasons for withdrawal

Reasons for withdrawal
Measure	Core Phase: Placebo; Extension Phase: up to 12 mg Perampanel Participants received perampanel-matched placebo tablets (6 tablets), orally, once daily before bedtime from Week 0 up to Week 18 (up to 19 weeks) in the Core Phase. Participants received placebo in Extension Phase as they received in Core Phase, orally, once daily before bedtime from Week 19 to Week 22 (preconversion period). Participants started receiving perampanel 2 mg tablet, orally, once daily which was then titrated as 2 mg weekly increments up to a maximum dose of 12 mg, orally, once daily up to Week 28 (conversion period). All participants could have their dose down or up titrated until an optimal dose was reached. After the conversion period, participants entered a maintenance period in which they received the perampanel dose orally, once daily, that provided the optimal combination of efficacy and tolerability before bedtime up to Week 75 or longer depending on the requirements of each country in the Extension Phase.	Core Phase: Perampanel 4 mg; Extension Phase: up to 12 mg Perampanel Participants received perampanel 2 mg tablet, orally, once daily before bedtime in Week 0 and then titrated up to maximum dose of 4 mg orally, once daily from Week 1 up to Week 5 (titration period), followed by perampanel 4 mg, orally, once daily from Week 6 up to Week 18 (maintenance period) in the Core Phase. Total duration of titration and maintenance period in Core Phase was 19 weeks. Participants received the same dose of perampanel 4 mg in Extension Phase as they received in Core Phase, orally, once daily before bedtime from Week 19 to Week 22 (preconversion period). Participants started receiving perampanel 4 mg tablet, orally, once daily which was then titrated as 2 mg weekly increments up to a maximum dose of 12 mg, orally, once daily up to Week 28 (conversion period). All participants could have their dose down or up titrated until an optimal dose was reached. After the conversion period, participants entered a maintenance period in which they received the perampanel dose orally, once daily, that provided the optimal combination of efficacy and tolerability before bedtime up to Week 75 or longer depending on the requirements of each country in the Extension Phase.	Core Phase: Perampanel 8 mg; Extension Phase: up to 12 mg Perampanel Participants received perampanel 2 mg tablet, orally, once daily before bedtime in Week 0 and then titrated up to maximum dose of 8 mg (weekly increment of 2 mg from Week 1 up to Week 3) orally, once daily for up to Week 5 (titration period), followed by perampanel 8 mg, orally, once daily from Week 6 up to Week 18 (maintenance period) in the Core Phase. Total duration of titration and maintenance period was 19 weeks in the Core Phase. Participants received the same dose of perampanel 8 mg in the Extension Phase as they received in Core Phase, orally, once daily before bedtime from Week 19 to Week 22 (preconversion period). Participants started receiving perampanel 8 mg tablet, orally, once daily which was then titrated as 2 mg weekly increments up to a maximum dose of 12 mg, orally, once daily up to Week 28 (conversion period). All participants could have their dose down or up titrated until an optimal dose was reached. After the conversion period, participants entered a maintenance period in which they received the perampanel dose orally, once daily, that provided the optimal combination of efficacy and tolerability before bedtime up to Week 75 or longer depending on the requirements of each country in the Extension Phase.	Core Phase/Extension Phase: up to 12 mg Perampanel Participants received perampanel 2 mg tablet, orally, once daily before bedtime in Week 0 and then titrated up to maximum dose of 12 mg (weekly increment of 2 mg from Week 1 up to Week 5) orally, once daily for up to Week 5 (titration period), followed by perampanel 12 mg, orally, once daily from Week 6 up to Week 18 (maintenance period) in the Core Phase. Total duration of titration and maintenance period was 19 weeks in the Core Phase. Participants received the same dose of perampanel 12 mg in the Extension Phase as they received in Core Phase, orally, once daily before bedtime from Week 19 to Week 22 (preconversion period) and continued receiving perampanel 12 mg, orally, once daily up to Week 28 (conversion period). All participants could have their dose down or up titrated until an optimal dose was reached. After the conversion period, participants entered a maintenance period in which they received the perampanel dose orally, once daily, that provided the optimal combination of efficacy and tolerability before bedtime up to Week 75 or longer depending on the requirements of each country in the Extension Phase.
Core Phase Adverse Event	4	5	15	20
Core Phase Lost to Follow-up	0	0	1	0
Core Phase Withdrawal by Subject	16	11	9	13
Core Phase Pregnancy	2	0	0	0
Core Phase Lack of Efficacy	1	2	1	1
Core Phase Other than specified	1	2	2	2
Core Phase Not treated	1	0	2	0
Extension Phase Lack of Efficacy	17	33	26	24
Extension Phase Pregnancy	2	0	1	1
Extension Phase Withdrawal by Subject	43	48	42	33
Extension Phase Adverse Event	18	16	9	20
Extension Phase Lost to Follow-up	2	1	1	1
Extension Phase Other than specified	13	18	13	18

Baseline Characteristics

A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Core Phase: Placebo n=176 Participants Participants received perampanel-matched placebo tablets (6 tablets), orally, once daily before bedtime from Week 0 up to Week 18 (up to 19 weeks).	Core Phase: Perampanel 4 mg n=176 Participants Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 4 mg orally once daily from Week 1 up to Week 5 (titration period), followed by perampanel 4 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.	Core Phase: Perampanel 8 mg n=175 Participants Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 8 mg (weekly increment of 2 mg from Week 1 up to Week 3) orally once daily for up to Week 5 (titration period), followed by perampanel 8 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.	Core Phase: Perampanel 12 mg n=180 Participants Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 12 mg (weekly increment of 2 mg from Week 1 up to Week 5) orally once daily for up to Week 5 (titration period), followed by perampanel 12 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.	Total n=707 Participants Total of all reporting groups
Age, Continuous	34.5 years STANDARD_DEVIATION 13.21 • n=5 Participants	33.1 years STANDARD_DEVIATION 13.18 • n=7 Participants	33.6 years STANDARD_DEVIATION 14.11 • n=5 Participants	32.3 years STANDARD_DEVIATION 12.30 • n=4 Participants	33.4 years STANDARD_DEVIATION 13.21 • n=21 Participants
Sex: Female, Male Female	90 Participants n=5 Participants	94 Participants n=7 Participants	84 Participants n=5 Participants	93 Participants n=4 Participants	361 Participants n=21 Participants
Sex: Female, Male Male	86 Participants n=5 Participants	82 Participants n=7 Participants	91 Participants n=5 Participants	87 Participants n=4 Participants	346 Participants n=21 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	2 Participants n=21 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	176 Participants n=5 Participants	175 Participants n=7 Participants	175 Participants n=5 Participants	179 Participants n=4 Participants	705 Participants n=21 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Race (NIH/OMB) Asian	169 Participants n=5 Participants	168 Participants n=7 Participants	159 Participants n=5 Participants	171 Participants n=4 Participants	667 Participants n=21 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Race (NIH/OMB) White	7 Participants n=5 Participants	7 Participants n=7 Participants	14 Participants n=5 Participants	7 Participants n=4 Participants	35 Participants n=21 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	2 Participants n=4 Participants	4 Participants n=21 Participants

PRIMARY outcome

Timeframe: Baseline, Week 19

Population: Intent-to-treat (ITT) Analysis Set included all participants who signed informed consent, were randomized, received at least one dose of study medication, and had at least one postdose seizure frequency data.

Outcome measures

Outcome measures
Measure	Placebo n=175 Participants Participants received perampanel-matched placebo tablets (6 tablets), orally, once daily before bedtime from Week 0 up to Week 18 (up to 19 weeks).	Perampanel 4 mg n=174 Participants Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 4 mg orally once daily from Week 1 up to Week 5 (titration period), followed by perampanel 4 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.	Perampanel 8 mg n=175 Participants Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 8 mg (weekly increment of 2 mg from Week 1 up to Week 3) orally once daily for up to Week 5 (titration period), followed by perampanel 8 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.	Perampanel 12 mg n=180 Participants Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 12 mg (weekly increment of 2 mg from Week 1 up to Week 5) orally once daily for up to Week 5 (titration period), followed by perampanel 12 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.
Core Phase: Percent Change in Seizure Frequency (For All Partial Seizures) Per 28 Days in the Randomization Phase Relative to Pre-randomization Phase (Baseline)	-10.76 percent change Interval -90.4 to 400.0	-17.32 percent change Interval -97.1 to 473.4	-28.95 percent change Interval -100.0 to 809.4	-38.03 percent change Interval -100.0 to 456.8

SECONDARY outcome

Timeframe: Baseline, Week 19

Responder rate was percentage of participants with greater than or equal to (\>=) 50% reduction in seizure frequency during maintenance period of the randomization phase relative to prerandomization phase (baseline). If the reduction in seizure frequency is less than (\<) 50%, then the participants are considered as non-responders.

Outcome measures

Outcome measures
Measure	Placebo n=175 Participants Participants received perampanel-matched placebo tablets (6 tablets), orally, once daily before bedtime from Week 0 up to Week 18 (up to 19 weeks).	Perampanel 4 mg n=174 Participants Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 4 mg orally once daily from Week 1 up to Week 5 (titration period), followed by perampanel 4 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.	Perampanel 8 mg n=175 Participants Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 8 mg (weekly increment of 2 mg from Week 1 up to Week 3) orally once daily for up to Week 5 (titration period), followed by perampanel 8 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.	Perampanel 12 mg n=180 Participants Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 12 mg (weekly increment of 2 mg from Week 1 up to Week 5) orally once daily for up to Week 5 (titration period), followed by perampanel 12 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.
Core Phase: Responder Rate During the Maintenance Period of the Randomization Phase Relative to the Prerandomization Phase (Baseline)- Last Observation Carried Forward (LOCF)	19.4 percentage of participants	23.0 percentage of participants	36.0 percentage of participants	43.3 percentage of participants

SECONDARY outcome

Timeframe: Baseline, Week 19

Population: ITT Analysis Set included all participants who signed informed consent, were randomized, received at least one dose of study medication, and had at least one postdose seizure frequency data. Here "overall number of participants analyzed" signifies participants who were evaluable for this outcome measure.

Seizure frequency was based on number of seizures per 28 days, calculated as the number of seizures over the entire time interval divided by the number of days in the interval and multiplied by 28. A complex partial seizure is a type of seizure that arises in one lobe of the brain, rather than the whole brain and it affects awareness and may cause in loss of consciousness. Secondary generalized seizures begin in one part of the brain, but then spread to both sides of the brain.

Outcome measures

Outcome measures
Measure	Placebo n=158 Participants Participants received perampanel-matched placebo tablets (6 tablets), orally, once daily before bedtime from Week 0 up to Week 18 (up to 19 weeks).	Perampanel 4 mg n=151 Participants Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 4 mg orally once daily from Week 1 up to Week 5 (titration period), followed by perampanel 4 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.	Perampanel 8 mg n=157 Participants Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 8 mg (weekly increment of 2 mg from Week 1 up to Week 3) orally once daily for up to Week 5 (titration period), followed by perampanel 8 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.	Perampanel 12 mg n=167 Participants Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 12 mg (weekly increment of 2 mg from Week 1 up to Week 5) orally once daily for up to Week 5 (titration period), followed by perampanel 12 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.
Core Phase: Percent Change in Seizure Frequency Per 28 Days For Complex Partial Seizures Plus Secondary Generalized Seizures in the Randomization Phase Relative to the Prerandomization Phase (Baseline)	-11.70 percent change Interval -88.6 to 400.0	-19.08 percent change Interval -100.0 to 410.0	-33.68 percent change Interval -100.0 to 1103.4	-41.80 percent change Interval -100.0 to 456.8

SECONDARY outcome

Timeframe: Baseline, Week 19

The investigator evaluated each participant for CGIC questionnaire to assess change in participant's disease clinical status from baseline. Assessment evaluated frequency of seizures, severity of seizures, occurrence of adverse events (AEs), and overall functional status of the participant using the 7-point scale. The evaluation used a 7-point scale with the scores 1: Very much improved, 2: Much improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse, 7: Very much worse. Lower score indicated improvement and higher score indicated worsening.

Outcome measures

Outcome measures
Measure	Placebo n=175 Participants Participants received perampanel-matched placebo tablets (6 tablets), orally, once daily before bedtime from Week 0 up to Week 18 (up to 19 weeks).	Perampanel 4 mg n=174 Participants Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 4 mg orally once daily from Week 1 up to Week 5 (titration period), followed by perampanel 4 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.	Perampanel 8 mg n=175 Participants Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 8 mg (weekly increment of 2 mg from Week 1 up to Week 3) orally once daily for up to Week 5 (titration period), followed by perampanel 8 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.	Perampanel 12 mg n=180 Participants Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 12 mg (weekly increment of 2 mg from Week 1 up to Week 5) orally once daily for up to Week 5 (titration period), followed by perampanel 12 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.
Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores Very much improved	3 Participants	5 Participants	11 Participants	9 Participants
Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores Much improved	31 Participants	39 Participants	41 Participants	54 Participants
Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores Minimally improved	54 Participants	45 Participants	53 Participants	40 Participants
Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores No change	67 Participants	56 Participants	37 Participants	37 Participants
Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores Minimally worse	3 Participants	10 Participants	5 Participants	4 Participants
Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores Much worse	1 Participants	0 Participants	0 Participants	1 Participants
Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores Very much worse	0 Participants	0 Participants	0 Participants	1 Participants

Adverse Events

Core Phase: Placebo

Serious events: 10 serious events

Other events: 114 other events

Deaths: 1 deaths

Core Phase: Perampanel 4 mg

Serious events: 6 serious events

Other events: 119 other events

Deaths: 0 deaths

Core Phase: Perampanel 8 mg

Serious events: 7 serious events

Other events: 127 other events

Deaths: 1 deaths

Core Phase: Perampanel 12 mg

Serious events: 12 serious events

Other events: 155 other events

Deaths: 0 deaths

Extension Phase: Perampanel 12 mg

Serious events: 113 serious events

Other events: 618 other events

Deaths: 7 deaths

Serious adverse events

Serious adverse events
Measure	Core Phase: Placebo n=176 participants at risk Participants received perampanel-matched placebo tablets (6 tablets), orally, once daily before bedtime from Week 0 up to Week 18 (up to 19 weeks).	Core Phase: Perampanel 4 mg n=176 participants at risk Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 4 mg orally once daily from Week 1 up to Week 5 (titration period), followed by perampanel 4 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.	Core Phase: Perampanel 8 mg n=175 participants at risk Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 8 mg (weekly increment of 2 mg from Week 1 up to Week 3) orally once daily for up to Week 5 (titration period), followed by perampanel 8 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.	Core Phase: Perampanel 12 mg n=180 participants at risk Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 12 mg (weekly increment of 2 mg from Week 1 up to Week 5) orally once daily for up to Week 5 (titration period), followed by perampanel 12 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.	Extension Phase: Perampanel 12 mg n=679 participants at risk Participants received the same dose of perampanel in Extension Phase as they received in Core Phase, orally, once daily before bedtime from Week 19 to Week 22 (preconversion period). This dose was then titrated as 2 mg weekly increments up to a maximum dose of 12 mg, orally once daily up to Week 28 (conversion period). Participants who received perampanel matched-placebo in Core Phase were given perampanel 2 mg weekly increments up to a maximum dose of 12 mg, orally once daily up to Week 28 (conversion period). All participants were allowed to have their dose down or up titrated until an optimal dose was reached. A maintenance period was followed by conversion period in which participants received perampanel dose of 12 mg, orally, once daily, that provided the optimal combination of efficacy and tolerability before bedtime up to Week 75 or longer depending on the requirements of each country.
Gastrointestinal disorders Haemorrhoids	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Death	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Sudden cardiac death	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Anal abscess	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Cellulitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Pneumonia	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Pyelonephritis acute	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Renal abscess	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Brain contusion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Burns second degree	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Facial bones fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Road traffic accident	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Contusion	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Epilepsy	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 7 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Status epilepticus	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.88% 6/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Complex partial seizures	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Convulsion	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Haemorrhage intracranial	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Partial seizures with secondary generalisation	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Grand mal convulsion	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Aggression	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Suicide attempt	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Acute psychosis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Conversion disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Self-injurious ideation	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Adenomyosis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Excessive granulation tissue	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Surgical and medical procedures Abortion induced	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Vascular disorders Aneurysm	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Vascular disorders Thrombophlebitis superficial	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Acute promyelocytic leukaemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Emotional disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign hydatidiform mole	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Brain neoplasm	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Fibroadenoma of breast	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Pregnancy, puerperium and perinatal conditions Pregnancy	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Sudden unexplained death in epilepsy	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Anxiety	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Anxiety disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Bipolar disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Delusion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Hallucination, auditory	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Irritability	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Mental disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Postictal psychosis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Psychogenic seizure	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Psychotic disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Psychotic disorder due to a general medical condition	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Suicidal behaviour	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Ankle fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Clavicle fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Fibula fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Foot fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Head injury	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Intentional overdose	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Ligament injury	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Limb injury	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Lumbar vertebral fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Meniscus injury	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Patella fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Pelvic fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Skin laceration	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Spinal compression fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Thermal burn	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Cardiac disorders Acute myocardial infarction	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Cardiac disorders Myocardial infarction	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Cardiac disorders Sinus node dysfunction	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Asphyxia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Pneumonia aspiration	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Blood and lymphatic system disorders Immune thrombocytopenic purpura	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Altered state of consciousness	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Ataxia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Cerebral infarction	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Cerebrovascular accident	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Dizziness	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Dysarthria	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Focal dyscognitive seizures	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Generalised tonic-clonic seizure	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Idiopathic partial epilepsy	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Lacunar infarction	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Limbic encephalitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Normal pressure hydrocephalus	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Seizure	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Seizure cluster	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Somnolence	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Subarachnoid haemorrhage	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Cataract	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Lens dislocation	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Diarrhoea	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Enterocolitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Gingival hypertrophy	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Haematemesis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Ureterolithiasis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Urinary retention	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Hepatobiliary disorders Cholelithiasis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Rash	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Rotator cuff syndrome	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Diabetes mellitus	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Appendicitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Gastroenteritis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Herpes zoster	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Lung infection	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Nasopharyngitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Periodontitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Pharyngitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Post procedural infection	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Sepsis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Urinary tract infection	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.

Other adverse events

Other adverse events
Measure	Core Phase: Placebo n=176 participants at risk Participants received perampanel-matched placebo tablets (6 tablets), orally, once daily before bedtime from Week 0 up to Week 18 (up to 19 weeks).	Core Phase: Perampanel 4 mg n=176 participants at risk Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 4 mg orally once daily from Week 1 up to Week 5 (titration period), followed by perampanel 4 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.	Core Phase: Perampanel 8 mg n=175 participants at risk Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 8 mg (weekly increment of 2 mg from Week 1 up to Week 3) orally once daily for up to Week 5 (titration period), followed by perampanel 8 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.	Core Phase: Perampanel 12 mg n=180 participants at risk Participants received perampanel 2 mg tablet, orally once daily before bedtime in Week 0 and then titrated up to maximum dose of 12 mg (weekly increment of 2 mg from Week 1 up to Week 5) orally once daily for up to Week 5 (titration period), followed by perampanel 12 mg, orally once daily from Week 6 up to Week 18 (maintenance period). Total duration of titration and maintenance period is 19 weeks.	Extension Phase: Perampanel 12 mg n=679 participants at risk Participants received the same dose of perampanel in Extension Phase as they received in Core Phase, orally, once daily before bedtime from Week 19 to Week 22 (preconversion period). This dose was then titrated as 2 mg weekly increments up to a maximum dose of 12 mg, orally once daily up to Week 28 (conversion period). Participants who received perampanel matched-placebo in Core Phase were given perampanel 2 mg weekly increments up to a maximum dose of 12 mg, orally once daily up to Week 28 (conversion period). All participants were allowed to have their dose down or up titrated until an optimal dose was reached. A maintenance period was followed by conversion period in which participants received perampanel dose of 12 mg, orally, once daily, that provided the optimal combination of efficacy and tolerability before bedtime up to Week 75 or longer depending on the requirements of each country.
Eye disorders Cataract	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Chalazion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Blood and lymphatic system disorders Anaemia	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.8% 12/679 • Number of events 13 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Blood and lymphatic system disorders Lymphadenitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Blood and lymphatic system disorders Eosinophilia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Blood and lymphatic system disorders Iron deficiency anaemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Blood and lymphatic system disorders Leukopenia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Blood and lymphatic system disorders Neutropenia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Cardiac disorders Angina pectoris	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Cardiac disorders Atrial fibrillation	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Ear and labyrinth disorders Vertigo	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/176 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.9% 5/175 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.2% 4/180 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.4% 23/679 • Number of events 25 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Ear and labyrinth disorders Cerumen impaction	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Ear and labyrinth disorders Tinnitus	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Vision blurred	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/180 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.8% 12/679 • Number of events 13 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Asthenopia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Conjunctivitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Diplopia	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.6% 11/679 • Number of events 12 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Eyelid oedema	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Visual impairment	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Conjunctival haemorrhage	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Dry eye	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Dysmetropsia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Glaucoma	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Keratoconjunctivitis sicca	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Normal tension glaucoma	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Retinal disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Vitreous floaters	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Eye pain	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Lacrimation increased	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Nausea	3.4% 6/176 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.3% 4/176 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.3% 4/175 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	5.6% 10/180 • Number of events 10 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	5.2% 35/679 • Number of events 37 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Diarrhoea	3.4% 6/176 • Number of events 7 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/176 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.3% 4/175 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.3% 6/180 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	4.9% 33/679 • Number of events 42 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Stomatitis	0.57% 1/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.9% 5/175 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/180 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.7% 25/679 • Number of events 35 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Constipation	0.57% 1/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.9% 5/175 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	4.0% 27/679 • Number of events 36 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Vomiting	4.0% 7/176 • Number of events 8 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/180 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.5% 24/679 • Number of events 25 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Abdominal discomfort	1.7% 3/176 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.6% 11/679 • Number of events 13 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Abdominal pain	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.9% 13/679 • Number of events 15 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Dyspepsia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/175 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.6% 11/679 • Number of events 11 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Gastritis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.0% 7/679 • Number of events 7 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Toothache	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.5% 10/679 • Number of events 10 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Abdominal pain lower	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Cheilitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Dental caries	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.4% 23/679 • Number of events 25 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Gingivitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.88% 6/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Abdominal pain upper	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.2% 8/679 • Number of events 8 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Aphthous stomatitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Colonic polyp	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Crohn's disease	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Gingival bleeding	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Gingival hyperplasia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Gingival pain	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Gingival ulceration	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Haemorrhoids	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Oral disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Oral pain	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Periodontal disease	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Reflux oesophagitis	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Salivary hypersecretion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Dry mouth	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Enteritis	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Epigastric discomfort	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Gastritis atrophic	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Lip dry	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Periodontitis	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Irritability	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	4.5% 8/176 • Number of events 9 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	5.7% 10/175 • Number of events 10 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	5.0% 9/180 • Number of events 9 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Fatigue	2.8% 5/176 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.3% 4/176 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.4% 6/175 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	5.0% 9/180 • Number of events 9 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	5.0% 34/679 • Number of events 36 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Gait disturbance	1.7% 3/176 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.3% 4/175 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	5.0% 9/180 • Number of events 9 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	4.1% 28/679 • Number of events 34 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Pyrexia	1.7% 3/176 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.3% 4/175 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.2% 4/180 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	5.7% 39/679 • Number of events 90 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Asthenia	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.5% 17/679 • Number of events 20 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Malaise	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Feeling abnormal	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.88% 6/679 • Number of events 7 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Device breakage	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Face oedema	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Foreign body reaction	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Influenza like illness	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Oedema	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Chest discomfort	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.2% 8/679 • Number of events 9 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Pain	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Hepatobiliary disorders Hepatic function abnormal	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.88% 6/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Hepatobiliary disorders Cholecystitis	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Immune system disorders Allergy to arthropod sting	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Immune system disorders Seasonal allergy	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Nasopharyngitis	14.8% 26/176 • Number of events 26 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	13.1% 23/176 • Number of events 23 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	13.7% 24/175 • Number of events 30 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	12.8% 23/180 • Number of events 28 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	25.0% 170/679 • Number of events 325 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Upper respiratory tract infection	4.5% 8/176 • Number of events 9 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	4.5% 8/176 • Number of events 12 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	8.0% 14/175 • Number of events 17 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	6.1% 11/180 • Number of events 19 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	10.3% 70/679 • Number of events 147 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Pharyngitis	1.7% 3/176 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.3% 4/175 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.5% 24/679 • Number of events 36 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Influenza	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/176 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	4.6% 31/679 • Number of events 36 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Gastroenteritis	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.7% 18/679 • Number of events 20 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Tinea pedis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.2% 8/679 • Number of events 9 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Bronchitis	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.0% 7/679 • Number of events 7 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Gastroenteritis viral	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Oral herpes	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Rhinitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.8% 12/679 • Number of events 13 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Bacterial infection	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Gastroenteritis bacterial	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Herpes zoster	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Impetigo	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Otitis externa	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.2% 8/679 • Number of events 10 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Otitis media	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Pneumonia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.0% 7/679 • Number of events 7 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Purulence	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Respiratory tract infection	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Sinusitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Syphilis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Tonsillitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.88% 6/679 • Number of events 8 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Urinary tract infection	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.2% 8/679 • Number of events 10 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Viral infection	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Wound infection	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Eczema infected	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Onychomycosis	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Contusion	2.3% 4/176 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.8% 5/176 • Number of events 19 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.4% 6/175 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.8% 5/180 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	7.2% 49/679 • Number of events 81 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Joint sprain	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/176 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/180 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Excoriation	1.7% 3/176 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Foot fracture	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.8% 12/679 • Number of events 13 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Skin laceration	1.7% 3/176 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.1% 21/679 • Number of events 21 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Thermal burn	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.1% 14/679 • Number of events 15 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Wound	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.2% 8/679 • Number of events 9 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Animal bite	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Fall	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.1% 14/679 • Number of events 20 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Head injury	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.6% 11/679 • Number of events 13 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Limb injury	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.2% 8/679 • Number of events 8 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Lip injury	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Rib fracture	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Ankle fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Arthropod sting	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Burns second degree	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Heat stroke	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Joint dislocation	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Ligament rupture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Multiple injuries	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Periorbital haematoma	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Radius fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Road traffic accident	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Stab wound	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Sunburn	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Tibia fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Tooth fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Tooth injury	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Wrist fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Forearm fracture	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Scratch	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Weight increased	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	4.0% 7/176 • Number of events 8 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.4% 6/175 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.3% 6/180 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	5.9% 40/679 • Number of events 44 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Blood creatine phosphokinase increased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.8% 5/180 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.5% 24/679 • Number of events 32 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Electrocardiogram QT prolonged	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.2% 4/180 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.3% 9/679 • Number of events 13 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Blood phosphorus decreased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.3% 9/679 • Number of events 10 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Protein urine present	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.8% 12/679 • Number of events 14 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Weight decreased	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.9% 13/679 • Number of events 14 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Blood cholesterol increased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Blood uric acid increased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.0% 7/679 • Number of events 7 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Gamma-glutamyltransferase increased	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations White blood cell count decreased	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Alanine aminotransferase increased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Aspartate aminotransferase increased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Blood parathyroid hormone abnormal	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Blood sodium decreased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Blood triglycerides abnormal	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Eosinophil count increased	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Monocyte count increased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Neutrophil count decreased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Platelet count decreased	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Red blood cells urine	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Urine ketone body present	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Vitamin D decreased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Blood glucose increased	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Blood triglycerides increased	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Blood urine present	0.57% 1/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Decreased appetite	1.7% 3/176 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.9% 5/175 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/180 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.1% 21/679 • Number of events 21 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.5% 10/679 • Number of events 12 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Increased appetite	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/180 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.88% 6/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Dyslipidaemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.88% 6/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Hyperlipidaemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/175 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.0% 7/679 • Number of events 8 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Diabetes mellitus	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Hypochloraemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Dehydration	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Hypertriglyceridaemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 7 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Weight fluctuation	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Appetite disorder	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Hyperglycaemia	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.3% 4/175 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.88% 6/679 • Number of events 7 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Back pain	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.9% 20/679 • Number of events 22 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Myalgia	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.0% 7/679 • Number of events 7 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.5% 10/679 • Number of events 13 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.3% 9/679 • Number of events 9 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Musculoskeletal stiffness	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Pain in extremity	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.1% 14/679 • Number of events 15 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Monarthritis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Muscle twitching	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Myokymia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Tenosynovitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Flank pain	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Neck pain	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Osteoarthritis	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lipoma	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Dizziness	5.7% 10/176 • Number of events 11 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	22.7% 40/176 • Number of events 48 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	28.6% 50/175 • Number of events 60 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	42.2% 76/180 • Number of events 85 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	46.7% 317/679 • Number of events 435 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Somnolence	13.1% 23/176 • Number of events 24 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	15.9% 28/176 • Number of events 28 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	17.7% 31/175 • Number of events 36 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	17.8% 32/180 • Number of events 33 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	24.3% 165/679 • Number of events 199 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Headache	7.4% 13/176 • Number of events 18 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	6.8% 12/176 • Number of events 22 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	7.4% 13/175 • Number of events 14 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	5.6% 10/180 • Number of events 11 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	13.8% 94/679 • Number of events 164 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Ataxia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.9% 7/180 • Number of events 8 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.2% 22/679 • Number of events 26 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Balance disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.3% 4/176 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.2% 4/180 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.5% 17/679 • Number of events 18 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Dysarthria	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/175 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.2% 4/180 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.2% 22/679 • Number of events 24 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Hypoaesthesia	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/176 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.8% 12/679 • Number of events 17 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Tremor	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/180 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.8% 19/679 • Number of events 23 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Convulsion	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Memory impairment	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.1% 14/679 • Number of events 16 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Nystagmus	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Amnesia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.3% 9/679 • Number of events 9 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Complex partial seizures	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Dementia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Lethargy	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.88% 6/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Paraesthesia	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Aphasia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Clumsiness	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Cranial nerve disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Dizziness postural	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Dysaesthesia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Dyskinesia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Dystonia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Head discomfort	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Hypersomnia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 7 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Migraine	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Myoclonus	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Nerve root compression	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Psychomotor hyperactivity	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Sensory disturbance	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Anaesthesia	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Dyslalia	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Grand mal convulsion	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Partial seizures with secondary generalisation	1.7% 3/176 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Syncope	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Tongue biting	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Pregnancy, puerperium and perinatal conditions Pregnancy	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Aggression	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.3% 4/176 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.9% 5/175 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.2% 4/180 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.2% 22/679 • Number of events 24 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Suicidal ideation	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/176 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	4.0% 7/175 • Number of events 7 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.1% 21/679 • Number of events 28 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Anxiety	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.4% 6/175 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.2% 22/679 • Number of events 22 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Insomnia	4.0% 7/176 • Number of events 7 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/176 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/180 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.7% 25/679 • Number of events 27 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Mood swings	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/176 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.8% 12/679 • Number of events 13 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Anger	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.7% 3/180 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.3% 9/679 • Number of events 9 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Depression	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.4% 16/679 • Number of events 19 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Affect lability	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.88% 6/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Depressed mood	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Abnormal behaviour	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Hallucination, auditory	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Mood altered	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Sleep disorder	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.0% 7/679 • Number of events 8 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Affective disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Agitation	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Anxiety disorder	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Confusional arousal	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Emotional disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Expressive language disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Fear	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Impatience	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Nervousness	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Obsessive-compulsive disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Personality change	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Personality disorder	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Regressive behaviour	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Restlessness	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Self-injurious ideation	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Sleep talking	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Soliloquy	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Stubbornness	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Suicide attempt	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.0% 7/679 • Number of events 7 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Thinking abnormal	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Tic	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Abnormal dreams	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Acute stress disorder	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Intentional self-injury	0.57% 1/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Panic attack	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Dysuria	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Bladder irritation	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Calculus ureteric	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Hypertonic bladder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Nephrolithiasis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Neurogenic bladder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Nocturia	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Polyuria	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Proteinuria	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.88% 6/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Urinary incontinence	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Haematuria	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Pollakiuria	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Prostatitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Cervical cyst	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Cervical polyp	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Hypomenorrhoea	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Menorrhagia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Menstrual disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Menstruation irregular	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Pelvic fluid collection	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Scrotal swelling	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Dysmenorrhoea	0.57% 1/176 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.9% 13/679 • Number of events 15 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.2% 8/679 • Number of events 10 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 10 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Upper respiratory tract inflammation	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Cough	1.1% 2/176 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.3% 9/679 • Number of events 9 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Productive cough	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	1.7% 3/176 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.3% 9/679 • Number of events 11 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Sneezing	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Wheezing	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Rash	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/175 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	5.0% 9/180 • Number of events 9 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	4.6% 31/679 • Number of events 37 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Pruritus	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.3% 4/175 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.9% 13/679 • Number of events 16 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Eczema	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.7% 18/679 • Number of events 20 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Dermatitis	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.9% 13/679 • Number of events 13 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Urticaria	2.3% 4/176 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/180 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.2% 8/679 • Number of events 9 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Heat rash	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Acne	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.0% 7/679 • Number of events 7 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Blister	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Dermatitis allergic	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Dermatitis atopic	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 9 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Dermatitis contact	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.88% 6/679 • Number of events 7 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.88% 6/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Eczema asteatotic	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Erythema	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Pityriasis alba	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Rash erythematous	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Rash papular	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Rash pruritic	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Skin burning sensation	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Skin erosion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Skin ulcer	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/175 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Alopecia	1.7% 3/176 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Night sweats	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Vascular disorders Hypertension	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Vascular disorders Hypotension	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.56% 1/180 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Vascular disorders Angiodysplasia	0.57% 1/176 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Arthropod bite	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Bone contusion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Bone fissure	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Burns first degree	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Chemical poisoning	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Chest injury	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Chillblains	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Clavicle fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Closed globe injury	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Concussion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Compression fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Conjunctival abrasion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Ear canal abrasion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Eye contusion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Eye injury	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Eyelid contusion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Eyelid injury	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Face injury	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Hand fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Heat illness	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Injury	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Joint injury	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Ligament injury	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Ligament sprain	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	3.4% 23/679 • Number of events 24 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Mouth injury	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Neck injury	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Patella fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Post-traumatic neck syndrome	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Procedural pain	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Scar	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Skin abrasion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.4% 16/679 • Number of events 18 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Skin injury	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Skin wound	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Soft tissue injury	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Subcutaneous haematoma	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Subdural haematoma	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Tooth dislocation	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Toxicity to various agents	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Injury, poisoning and procedural complications Upper limb fracture	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Anticonvulsant drug level increased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Blood bicarbonate decreased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Blood bilirubin increased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Blood creatinine decreased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Blood lactate dehydrogenase increased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Blood magnesium abnormal	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Blood phosphorus increased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Blood pressure increased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Blood sodium increased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Gamma-glutamyltransferase abnormal	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Liver function test abnormal	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Liver function test increased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Lymphocyte count decreased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Neutrophil count increased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Red blood cell count decreased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Red blood cells urine positive	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Thyroxine free decreased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations Urine uric acid increased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations White blood cell count increased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Investigations pH urine increased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Cardiac disorders Arteriosclerosis coronary artery	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Cardiac disorders Palpitations	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Cardiac disorders Tachycardia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Congenital, familial and genetic disorders Hypophosphatasia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Blood and lymphatic system disorders Lymphopenia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Blood and lymphatic system disorders Neutrophilia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Carpal tunnel syndrome	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Cerebral disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Change in seizure presentation	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Drooling	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Dysgeusia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Dysstasia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Epilepsy	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Focal dyscognitive seizures	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Hemiplegia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Hyposmia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Language disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Loss of consciousness	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Neuralgia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Neuropathy peripheral	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Postictal headache	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Postural tremor	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Radial nerve palsy	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Seizure	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	2.4% 16/679 • Number of events 19 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Seizure cluster	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Sleep deficit	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Slow response to stimuli	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Speech disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Status epilepticus	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Tonic convulsion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Visual field defect	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Vocal cord paralysis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Blepharitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Borderline glaucoma	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Conjunctival hyperaemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Conjunctivitis allergic	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 5 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Corneal erosion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Diabetic retinopathy	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Episcleritis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Excessive eye blinking	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Eye discharge	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Eye pruritus	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Eyelid myoclonus	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Foreign body sensation in eyes	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Keratitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Ocular hyperaemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Psychogenic visual disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Punctate keratitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Swelling of eyelid	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Visual acuity reduced	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Eye disorders Xerophthalmia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Ear and labyrinth disorders Deafness neurosensory	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Ear and labyrinth disorders Ear pain	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Ear and labyrinth disorders Ear pruritus	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Ear and labyrinth disorders Hypoacusis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Ear and labyrinth disorders Motion sickness	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Ear and labyrinth disorders Sudden hearing loss	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Ear and labyrinth disorders Vertigo positional	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Aphthous ulcer	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 7 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Breath odour	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Chronic gastritis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Dysphagia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Enterocolitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Faecaloma	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Faeces soft	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Food poisoning	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Gastric ulcer	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Gingival hypertrophy	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Glossitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Haemorrhoidal haemorrhage	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Ileus paralytic	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Irritable bowel syndrome	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Large intestine polyp	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Lip ulceration	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Lumbar hernia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Noninfective gingivitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Oesophagitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Oral contusion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Peptic ulcer	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Salivary gland mucocoele	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Calculus urinary	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Ketonuria	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Renal cyst	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Ureterolithiasis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Renal and urinary disorders Urinary retention	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Androgenetic alopecia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Anhidrosis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Dermal cyst	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Drug eruption	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Fracture blisters	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Hyperkeratosis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Ingrowing nail	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Miliaria	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Onychalgia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Palmoplantar keratoderma	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Pigmentation disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Candida infection	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Pruritus generalised	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Purpura	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Seborrhoeic dermatitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Skin discolouration	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Skin fissures	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Skin lesion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Skin and subcutaneous tissue disorders Swelling face	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Product Issues Device breakage	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Product Issues Product blister packaging issue	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Arthritis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Joint swelling	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Muscle tightness	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Osteoporosis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Periarthritis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Posture abnormal	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Spinal osteoarthritis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Spondylolisthesis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Systemic lupus erythematosus	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Musculoskeletal and connective tissue disorders Tendonitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Endocrine disorders Autoimmune thyroiditis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Endocrine disorders Hypothyroidism	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Hyperammonaemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Hypercholesterolaemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Hypermagnesaemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Hyperuricaemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.74% 5/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 6 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Hypoproteinaemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Metabolism and nutrition disorders Obesity	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Angular cheilitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Bartholin's abscess	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Carbuncle	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Cellulitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Chronic sinusitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Conjunctivitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.6% 11/679 • Number of events 12 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Cystitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Dermatophytosis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Dermatophytosis of nail	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Ear infection	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Eczema impetiginous	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Enteritis infectious	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Eye infection bacterial	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Folliculitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Fungal infection	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Fungal skin infection	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Gingival abscess	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Helicobacter infection	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Herpes dermatitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Hordeolum	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Infected dermal cyst	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Kidney infection	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Lung infection	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Mumps	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Oral candidiasis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Paronychia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Pericoronitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Peritonsillar abscess	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Pyoderma	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Tinea manuum	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Vaginal infection	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Varicella	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Infections and infestations Vulvovaginitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Vascular disorders Hyperaemia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Vascular disorders Orthostatic hypotension	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Vascular disorders Peripheral coldness	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Vascular disorders Phlebitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Surgical and medical procedures Tooth extraction	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Surgical and medical procedures Wisdom teeth removal	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Acrochordon	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign breast neoplasm	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign hepatobiliary neoplasm	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Leiomyoma	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin papilloma	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Uterine leiomyoma	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Social circumstances Hearing aid user	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Chest pain	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Chills	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Decreased activity	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Feeling hot	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Generalised oedema	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Oedema peripheral	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Peripheral swelling	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
General disorders Thirst	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Bipolar disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Bruxism	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Confusional state	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Conversion disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Delusion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Depressive symptom	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Dissociative disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Enuresis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Hallucination	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Impulsive behaviour	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Major depression	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Mania	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Mental disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Middle insomnia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Mixed anxiety and depressive disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Neurosis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Nightmare	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Panic disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Paranoia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Persecutory delusion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Persistent depressive disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Psychogenic seizure	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.59% 4/679 • Number of events 4 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Somatic symptom disorder	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Stress	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Suicidal behaviour	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Amenorrhoea	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Benign prostatic hyperplasia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Breast tenderness	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Genital haemorrhage	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Menopausal symptoms	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Menstruation delayed	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Oligomenorrhoea	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Ovarian cyst	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Pelvic pain	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Scrotal inflammation	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Sexual dysfunction	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Vaginal discharge	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Reproductive system and breast disorders Laryngeal discomfort	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Asthma	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Atelectasis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Hyperventilation	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Laryngeal inflammation	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Oropharyngeal discomfort	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.44% 3/679 • Number of events 3 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Pharyngeal inflammation	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Pneumonia aspiration	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Respiratory tract congestion	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Sputum increased	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Tonsillar inflammation	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Respiratory, thoracic and mediastinal disorders Vasomotor rhinitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Hepatobiliary disorders Cholelithiasis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.29% 2/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Hepatobiliary disorders Hepatic mass	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Hepatobiliary disorders Hepatic steatosis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Gingivitis	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	1.1% 2/176 • Number of events 2 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/679 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Gastrointestinal disorders Haematochezia	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Nervous system disorders Burning sensation	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.15% 1/679 • Number of events 1 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.
Psychiatric disorders Irritability	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/176 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/175 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	0.00% 0/180 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.	9.0% 61/679 • Number of events 72 • From the date of first dose up to 30 days after the last dose of study drug (up to Week 79) Planned safety analysis of Extension Phase included treatment emergent AEs on/after first day of perampanel treatment in entire study. Analysis set for Extension Phase included 679 participants: 596 had perampanel in Core Phase \& at least one dose of perampanel in Extension Phase, 83 had perampanel in Core Phase only. Participants received varying doses in Extension Phase depending on tolerance but as target dose was defined as 12 mg/day for all participants, AEs were summarized as a single arm.

Additional Information

Inquiry Service.

Eisai Co., Ltd.

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place